Guideline recommendations for heart complications in thalassemia major

Journal of Cardiovascular Medicine

Volumn 9, Issue 5, 2008, Pages 515-525

  Cogliandro, Tiziana ^a   Derchi, Giorgio ^b   Mancuso, Luigi ^c   Mayer, M Carolina ^d   Pannone, Bruno ^d   Pepe, Alessia ^e   Pili, Marcello ^f   Bina, Patrizio ^f   Cianciulli, Paolo ^a   De Sanctis, Vincenzo ^g   Maggio, Aurelio ^h  

^a S EUGENIO HOSPITAL   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c Laboratorio di Ecocardiografia   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^f Osp Regionale per le Microcitemie   (Italy)

^g UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^h UO Ematologia II con Talassemia   (Italy)

Author keywords

Heart complications recommendations; Iron overloading; Secondary hemochromatosis; Thalassemia

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; PLACEBO;

ASSISTED CIRCULATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EVALUATION; FOLLOW UP; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING; HEART RIGHT VENTRICLE FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HOLTER MONITORING; HUMAN; IRON OVERLOAD; ISOLATED MYOCARDIAL SIDEROSIS; LIFE EXPECTANCY; LUNG ARTERY PRESSURE; MEDICAL SOCIETY; METHODOLOGY; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; RADIOISOTOPE VENTRICULOGRAPHY; RECOMMENDED DRUG DOSE; REVIEW; SIDEROSIS; THALASSEMIA MAJOR;

BETA-THALASSEMIA; HEART DISEASES; HUMANS;

EID: 42049114471     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3282f20847     Document Type: Review

References (103)

1. Higgs DR, Thein SL, Woods WG. The molecular pathology of the thalassaemias. In: Weatherall DJ, Clegg B, editors. The thalassaemia syndromes, 4th edn Oxford: Blackwell Science; 2001. pp. 133-191.
2. Cappellini MD, Caruso V, Cianciulli P, Filosa A, Galanello R, Lai ME, et al. Guidelines for β-thalassemia intermedia. Emothal, Sett-Dic 2005; 3:37-46.
3. Rund D, Rachmilewitz E. Medical progress: beta-thalassemia. N Engl J Med 2005; 353:1135-1146.
4. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survival and complications in thalassemia. Ann NY Acad Sci 2005; 1054:40-47.
5. Olivieri NF, Nathan DG, McMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331:574-578.
6. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187-1193.
7. Kremastinos D, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 1993; 39:503-508.
8. Kremastinos D, Tiniakos G, Theodorakis GN, Vrettou H, Tsiapras D, Stavropoulos-Giokas CG. Myocarditis in beta-thalassemia major. A cause of heart failure. Circulation 1995; 91:66-70.
9. Mancuso L, Panzarella G, Bartolotta TV, Midiri M, Renda D, Maggio A. Cardiac complications in thalassemia: noninvasive detection methods and new directions in the clinical management. Expert Rev Cardiovasc Ther 2003; 1:439-452.
10. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97:3411-3416.
11. Tam DH, Farber HW. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and review of the literature. Am J Hematol 2006; 81:443-447.
12. Singer ST, Kuypers FA, Styles L, Vichinsky EP, Foote D, Rosenfeld H. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol 2006; 81:670-675.
13. Hahalis G, Manolis AS, Apostopoulos D, Alexopoulos D, Vagenakis AG, Zoumbos NC. Right ventricular cardiomyopathy in beta-thalassaemia major. Eur Heart J 2002; 23:147-151.
14. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001; 104:2996-3007.
15. Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, et al. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann NY Acad Sci 2005; 1054:386-395.
16. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360:516-520.
17. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006; 85:315-319.
18. Westwood MA, Anderson LJ, Maceira AM, Shah FT, Prescott E, Porter JB, et al. Normalized left ventricular volumes and functioning thalassemia major patients with normal myocardial iron. J Mag Reson Imaging 2007; 25:1147-1151.
19. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005; 127:1523-1530.
20. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2006; 8:417-426.
21. Maceira AM, Prasad SK, Khan M, Pennell DJ. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J 2006; 27:2879-2888.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from American Society of Echocardiography. J Am Soc Echocardiogr 2005; 18:1440-1463.
23. Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, Gozzard DI, Peters TJ. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980; 14:719-724.
24. Lombardo T, Tamburino C, Bartoloni G, Morrone ML, Frontini V, Italia F, et al. Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study. Ann Hematol 1995; 71:135-141.
25. Olson LJ, Edwards WD, McCall JT, Ilstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987; 10:1239-1243.
26. Durongpisitkul K, Kruasukon S, Kangkagate C, Tanphaichitr VS. Early detection of cardiac involvement in beta-thalassemia children. J Med Assoc Thai 2002; 85 (Suppl 2):S667-S673.
27. Sau F, Lai ME, Pargentino E, Seguro C, Pilloni MI, Lisci V, et al. Clinical and echocardiographic evaluation of thalassemic cardiomyopathy. Cardiologia 1995; 40:307-314.
28. Chrysohoou C, Panagiotakos DB, Barbetseas Y, Brilli S, Lambrou S, Karagiorga M, et al. Echocardiographic and electrocardiographic prognostic factors of heart failure in young patients with beta-thalassemia major: a 10-year (1995-2004) follow-up. Int J Hematol 2004; 80:336-340.
29. Gurses D, Ulger Z, Levent E, Aydinok Y, Ozyurek AR. Time domain heart rate variability analysis in patients with thalassaemia major. Acta Cardiol 2005; 60:477-481.
30. Qureshi N, Avasarala K, Foote D, Vichinsky EP. Utility of Holter electrocardiogram in iron-overloaded hemoglobinopathies. Ann NY Acad Sci 2005; 1054:476-480.
31. Cavallaro L, Meo A, Busa G, Coglitore A, Sergi G, Satullo G, et al. Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG. Minerva Cardioangiol 1993; 41 (7-8):297-301.
32. Kucuk NO, Aras G, Sipahi T, Ibis E, Akar N, Soylu A, Erbay G. Evaluation of cardiac functions in patients with thalassemia major. Ann Nucl Med 1999; 13:175-179.
33. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104:263-269.
34. Hahalis G, Manolis AS, Apostolopoulos D, Alexopoulos D, Vagenakis AG, Zoumbos NC. Right ventricular cardiomyopathy in beta-thalassaemia major. Eur Heart J 2002; 23:102-105.
35. Wandt B, Fornander Y, Egerlid R. Maximal longitudinal contraction velocity in assessment of left ventricular systolic function: a pused tissue Doppler and M-mode study. Echocardiography 2004; 21:587-592.
36. Hoglund C, Alam M, Thorstrand C. Atrioventricular plane displacement in healthy persons. An echocardiographic study. Acta Med Scand 1988; 224:557-562.
37. Gulati VK, Katz WE, Follandsbee WP, Gorcsan J. Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function. Am J Cardiol 1996; 77:979-984.
38. Nilsson B, Bojo L, Wandt B. Influence of body size and age on maximal systolic velocity of mitral annulus motion. Clin Physiol 2000; 20:272-278.
39. Kaul S, Tei C, Hopkins JM, Shah PM. Assesment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984; 107:526-531.
40. Meluzin J, Spiranova L, Bakala J, Toman J, Krejci J, Hude P, et al. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion. A new, rapid, and noninvasive method of evaluating right ventricular systolic motion. Eur Heart J 2001; 22:340-348.
41. Colle I, Moreau R, Godinho E, Kheir A, Le Pavec J, Sitbon O, Herve P. Diagnosis of porto-pulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37:401-409.
42. Castro M, Krowka MJ, Schroeder D, Beck KC, Plevak DJ, Rettke SR, et al. Frequency and clinical implications of increased pulmonary hypertension in liver transplant patients. Mayo Cln Proc 1996; 71:543-551.
43. Gharzuddine WS, Kazma HK, Nuwayhid IA, Bitar FF, Koussa SF, Moukarbel GV, Taher AT. Left ventricular diastolic function in beta-thalassaemia major. Evidence for an early stage of impaired relaxation. Eur J Echocardiogr 2002; 3:47-51.
44. Spirito P, Lupi G, Melevendi C, Vecchio C. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 1990; 1082:88-94.
45. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22:2171-2179.
46. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennel DJ. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial overload. J Magn Reson Imaging 2003; 18:33-39.
47. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 2005; 112:535-543.
48. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, et al. Evaluation of the efficacy of oral deferiprone in b-thalassemia major by multislice multiecho T2*. Eur J Haematol 2006; 76:183-192.
49. Pepe A, Positano V, Santarelli MF, Sorrentino F, De Marchi D, Maggio A, et al. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Res Imaging 2006; 23:662-668.
50. Anderson LJ, Westwood M, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127:348-355.
51. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107:3738-3744.
52. Sironi M, Lombardi M, Pepe A, De Marchi D. Study of heart function. In: Lombardi M, Bartolozzi C, editors. CMR of heart and vessels. Italia: Springer-Verlag; 2005.
53. Pepe A, Cracolici E, Positano V, Sorrentino F, De Marchi D, Lo Pinto C, et al. Myocardial fibrosis in b-thalassemia major by late gadoliniumenhanced magnetic resonance imaging: correlation with cardiac risk factors, biventricular function parameters, myocardial iron overload and ECG-changes [abstract]. Circulation 2005; 112:4794.
54. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, et al. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J 2004; 25:1940-1965.
55. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassemia major. Lancet 1989; 2:27-30.
56. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamineor deferiprone-treated patients with thalassemia major. Blood 2006; 107:3733-3737.
57. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomised clinical trial. Blood Cells Mol Dis 2002; 28:196-208.
58. Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr 2004; 41:21-27.
59. Olivieri NF, Koren G, Herman C, Bentur Y, Chung D, Klein J, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990; 336:1275-1279.
60. Olivieri NF, Brittenham GM. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO). Blood 1997; 90:264A.
61. Anderson LJ, Wonke B, Prescott E, Holden S, Walker M, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentration and ventricular function in beta-thalassaemia. Lancet 2002; 360:516-520.
62. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88:489-496.
63. Dolgin M. Nomenclature and criteria for diagnosis of disease of the heart and great vessels. The criteria committee of the New York Heart Association. Boston, Massachusetts: Little, Brown & Co. 1994. pp. 253-256.
64. Ceci A, Baiardi P, Felisi MG, Cappellini MD, Carnelli V, De Sanctis V, et al. The safety and effectiveness of deferiprone in a large scale 3 years study in Italian patients. Br J Haematol 2002; 118:330-336.
65. Hoffbrand AV, Al-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overload patients. Blood 1998; 91:295-300.
66. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005; 90:1309-1314.
67. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, et al. Iron chelation treatment with combined therapy with deferiprone and deferoxamine: a 12-month trial.. Blood Cells Mol Dis 2006; 36:21-25.
68. Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematol J 2004; 5:475-479.
69. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Khan M, et al. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Blood 2005; 106:3655.
70. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation 2007; 115:1876-1884.
71. Wu KH, Chang JSM, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regress severe heart failure in patients with beta-thalassemia major. Ann Hematol 2004; 83:471-473.
72. Tsironi M, Defteros S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005; 74:84-85.
73. Tavecchia L, Masera N, Russo P, Ciro A, Vincenzi A, Vimercati C, Masera G. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. Haematologica 2006; 91 (6 Suppl):ECR19.
74. Porcu M, Landis N, Salis S, Corda M, Orru P, Serra E, et al. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure. A case report. Eur J Heart Fail 2007; 9:320-322.
75. Miskin H, Yaniv I, Berant M, Heshko C, Tamary H. Reversal of cardiac complications in thalassaemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol 2003; 70:398-403.
76. Davis BA, Porter LB. Long-term outcome of continous 24-h deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassaemia. Blood 2000; 95:1229-1236.
77. Lai ME, Vacquer S, Pepe A, Maggio A, Carta MP, Cianciulli P, et al. Long-term outcome of iron-induced cardiac disease in patients with thalassaemia major treated with combined DFP/DFO or DFO alone. Blood 2006; 108:1764.
78. Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patients affected by severe type of juvenile hemochromatosis (JH). Blood 2007; 109:362-364.
79. Daraio F, Ryan E, Gleeson F, Roetto A, Crowe J, Camaschella C. Juvenile hemochromatosis due to G320V/Q116X compound heterozygosity of hemojuvelin in a Irish patient. Blood Cells Mol Dis 2005; 35:174-176.
80. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007; 138:407-421.
81. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107:3455-3462.
82. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomised phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusonal iron overload. Haematologica 2006; 91:873-880.
83. 2+ channels modifiers: possible implications in iron overload. Circ Res 1999; 84:1302.
84. Gitto E, Tau DX, Reiter RJ, Karbownik M, Manchester LC, Cuzzocrea S, et al. Individual and synergistic antioxidative actions of melatonin; studies with vitamin E, vitamin C, glutathione and desferrioxamine in rat liver. J Pharm Pharmacol 1997; 53:293.
85. Oettl K, Greilberger J, Zangger K, Haslinger E, Reibnegger G, Jurgens G. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem Pharmacol 2001; 62:241-248.
86. Rakel RE, Bope ET. Conn's current therapy. Rakel & Bope: Publisher's location? 2004.
87. Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM. Tissue Doppler echocardiography in patients with thalassemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J 2003; 24:113-119.
88. Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major witout producing excessive expansion of erythropoiesis. Transfusion 1997; 37:135.
89. Karvounis HI, Zaglavara TA, Parharidis GE, Nouskas IG, Hassapopoulou EP, Gemitzis KD, Louridas GE. An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with beta-thalassemia major. Am Heart J 2001; 141:281.
90. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:384-416.
91. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajd M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary. Eur Heart J 26; 2005:1115-1140.
92. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 1993; 70:357-362.
93. Koerner MM, Tenderich G, Minami K, zu Knyphausen E, Mannebach H, Kleesiek K, et al. Heart transplantation for end-stage heart failure causes by iron overload. Br J Haematol 1997; 97:293.
94. Perrimond H, Michel G, Orsini A, Kreitmann B, Metras D. First report of a cardiac transplantation in a patient with thalassemia major. Br J Haematol 1991; 78:467.
95. Olivieri NF, Liu PP, Sher GD, Daly PA, Greig PD, McCusker PJ, et al. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. N Engl J Med 1994; 330:1125-1127.
96. Caines AE, Kpodonu J, Massad MG, Chaer R, Evans A, Lee JC, Geha AS. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant 2005; 24:486-488.
97. Derchi G, Fonti A, Forni GL, Galliera EO, Cappellini MD, Turati F, Policlinico OM. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1999; 138:384.
98. Derchi G, Formisano F, Lamagna M, Galanello R, Bina P, Cappellini MD, et al. Incidence of pulmonary hypertension in haemoglobinopathic patients without left ventricular disfunction. Blood 2005; 106:2691.
99. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-587.
100. Littera R, La Nasa G, Derchi G, Cappellini MD, Chang CY, Contu L. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 2002; 100:1516-1517.
101. Derchi G, Forni GL, Formisano F, Cappellini MD, Galanello R, D'Ascola G, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005; 90:452-458.
102. Derchi G, Forni GL. Therapeutic approaches to pulmonary hypertension in hemoglobinopathies: Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathy. Ann NY Acad Sci 2005; 1054:471-475.
103. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25:2243-2278.